Monday 12th October 2026 13:00 - 14:00 (BST)
Global drug pricing is entering a new era of interdependence. International Reference Pricing (IRP) and Most Favoured Nation (MFN) clauses are accelerating price convergence across markets. Early pricing decisions in lower-price markets can cascade internationally, anchoring global price levels. As IRP expands and MFN clauses gain traction, industry leaders must adapt to a landscape where the lowest global price increasingly sets the benchmark and success often depends on early, cross-functional alignment embedding pricing and access strategy well before approval.
In this 60-minute masterclass, industry expert Andrew Cummins will highlight the critical 12–24 month post-launch window, where access strategy and pricing discipline determine global value outcomes. He will examine the growing importance of tiered launch sequencing to protect high-impact markets; the strategic use of early access programmes to enable supply without triggering IRP; and forward-looking pricing simulations to model global impact before launch.
This masterclass will equip you to optimise your global launch strategy in an increasingly interconnected pricing environment.
12th Oct 2026 13:00 – 14:00 (BST)
Are you ready to transform your skills and unlock your full potential? Now is the time to elevate your training.
Join Now